Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:05:15 EST Wed 11 Nov 2026
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR+ Search
SEDAR+ Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR+ Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
News for U:VKTX from 2025-11-12 to 2026-11-11 - 35 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2026-11-09 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek(TM) 2026
2026-11-03 16:30
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-11-03 09:00
U
U:VKTX
News Release
200
Peptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
2026-10-28 16:05
U
U:VKTX
News Release
200
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-10-21 16:05
U
U:VKTX
News Release
200
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
2026-10-14 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
2026-10-06 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
2026-09-28 16:30
U
U:VKTX
News Release
200
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
2026-09-24 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
2026-09-23 16:32
U
U:VKTX
News Release
200
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
2026-09-22 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
2026-09-02 16:05
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-07-29 16:05
U
U:VKTX
News Release
200
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-23 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
2026-07-22 16:05
U
U:VKTX
News Release
200
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
2026-06-24 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
2026-06-11 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
2026-05-21 07:05
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-05-13 08:30
U
U:VKTX
News Release
200
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
2026-05-12 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
2026-05-05 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
2026-04-29 16:05
U
U:VKTX
News Release
200
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-23 06:15
U
U:VKTX
News Release
200
The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
2026-04-22 16:35
U
U:VKTX
News Release
200
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
2026-04-10 07:30
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-03-26 07:05
U
U:VKTX
News Release
200
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
2026-03-05 16:03
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-02-11 16:05
U
U:VKTX
News Release
200
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-02-04 16:05
U
U:VKTX
News Release
200
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
2026-01-12 07:00
U
U:VKTX
News Release
200
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
2026-01-08 07:00
U
U:VKTX
News Release
200
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
2026-01-07 07:00
U
U:VKTX
News Release
200
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
2026-01-05 16:03
U
U:VKTX
News Release
200
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 16:05
U
U:VKTX
News Release
200
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
2025-11-19 02:55
U
U:VKTX
News Release
200
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735